Breaking News Instant updates and real-time market news.

AMRX

Amneal Pharmaceuticals

$13.33

-0.35 (-2.56%)

07:31
01/14/19
01/14
07:31
01/14/19
07:31

Amneal Pharmaceuticals receives FDA approval for generic version of Exelon Patch

Amneal Pharmaceuticals announced that it has received FDA approval for a generic version of Exelon Patch, 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The company is planning to commercialize its Rivastigmine Transdermal System shortly. According to IQVIA, U.S market annual sales for the 12 months ended November 2018 for Rivastigmine Transdermal System is estimated to be approximately $225M.

  • 28

    Feb

AMRX Amneal Pharmaceuticals
$13.33

-0.35 (-2.56%)

11/27/18
RBCM
11/27/18
NO CHANGE
RBCM
RBC Capital likes select Specialty Pharma names on recent sector selling
RBC Capital analyst Randall Stanicky is positive on Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Flexion Therapeutics (FLXN), Jazz Pharmaceuticals (JAZZ) as his top selections in Specialty Pharma, saying the sector has come under particular pressure in the most recent market sell-off. The analyst anticipates Amneal Pharmaceuticals to benefit from a cyclical generics recovery in the 2nd half of 2019, saying its "valuation is compelling against growth outlook". For Endo International, Stanicky sees the cellulite data driven selloff as overdone and believes that its low valuation helps to set a floor for the stock. For Flexion, the analyst anticipates a 2019 inflection on ramping Zilretta launch, adding that its 32% short interest is "hard to ignore". For Jazz Pharma, Stanicky points to a re-set of expectations around Vyxeos in Q3 as the company enters a "catalyst-heavy path led by December 20th solriamfetol PDUFA" and a material discount in valuation. The analyst maintain his Outperform rating on these four stocks.
12/14/18
MSCO
12/14/18
DOWNGRADE
MSCO
Equal Weight
Amneal Pharmaceuticals downgraded to Equal Weight at Morgan Stanley
12/14/18
MSCO
12/14/18
DOWNGRADE
Target $18
MSCO
Equal Weight
Amneal downgraded to Equal Weight on competition at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Amneal Pharmaceuticals to Equal Weight from Overweight, noting that Amneal has cut guidance due to worse than expected pressures on key drugs in its existing portfolio and he now anticipates additional risk. Risinger, who lowered out-year projections to reflect pressure on key franchises and more intense competition for new launches, lowered his price target on Amneal shares to $18 from $24.
01/03/19
LEER
01/03/19
NO CHANGE
Target $19
LEER
Outperform
Amneal Pharmaceuticals price target lowered to $19 from $25 at Leerink
Leerink analyst Ami Fadia lowered her price target for Amneal Pharmaceuticals to $19 from $25 to reflect a more conservative erosion of base business products like Gx Aggrenox, Vagifem, and Voltaren Gel into 2019, and a more conservative view on new product launches given continued lack of visibility into the timing and magnitude of such opportunities. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:54
01/22/19
01/22
07:54
01/22/19
07:54
Periodicals
Amazon launches direct sales of merchandise in Brazil, Reuters reports »

Amazon has launched…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

STAA

STAAR Surgical

$35.10

0.59 (1.71%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Recommendations
STAAR Surgical analyst commentary  »

Canaccord strongly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$213.94

2.23 (1.05%)

07:52
01/22/19
01/22
07:52
01/22/19
07:52
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

BX

Blackstone

$32.91

0.28 (0.86%)

07:51
01/22/19
01/22
07:51
01/22/19
07:51
Periodicals
Blackstone CEO doesn't think U.S. on verge of recession, CNBC reports »

Blackstone Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 11

    Feb

RDS.A

Royal Dutch Shell

$61.07

0.89 (1.48%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Downgrade
Royal Dutch Shell rating change  »

Royal Dutch Shell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMAC

DiaMedica Therapeutics

$3.50

-0.16 (-4.37%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Hot Stocks
DiaMedica Therapeutics announces publication of paper on KLK1, AIS »

DiaMedica Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.97

2.32 (2.02%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Alexion analyst commentary  »

Credit Suisse sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 04

    Feb

  • 18

    Feb

SMTX

SMTC Corp.

$5.60

0.12 (2.19%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Conference/Events
SMTC Corp. management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TIF

Tiffany

$89.85

4.6 (5.40%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HTHT

Huazhu Group

$34.94

1.94 (5.88%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
Huazhu Group initiated  »

Huazhu Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.97

0.18 (1.41%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
GreenTree Hospitality initiated  »

GreenTree Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.10

-0.135 (-2.58%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Conference/Events
TherapeuticsMD management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

ORTX

Orchard Therapeutics

$13.00

0.2 (1.56%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Hot Stocks
Orchard Therapeutics announces OTL-300 data published »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$62.51

1.99 (3.29%)

07:47
01/22/19
01/22
07:47
01/22/19
07:47
Hot Stocks
Jacobs Engineering awarded $93M contract for California WaterFix program »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 19

    Feb

STT

State Street

$71.19

0.07 (0.10%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.